Education
About Us
Working with TipRanks
Follow Us
Herve Hoppenot Insider Profile
4 Followers
Herve Hoppenot, Director at Incyte, holds 329.65K shares in Incyte (Ticker: INCY), holds 12.50K shares in Bicycle Therapeutics (Ticker: BCYC), holds ― shares in Maze Therapeutics, Inc. (Ticker: MAZE). Most recently, Herve Hoppenot Sold ― shares of Incyte on Nov 12, 2025 for an estimated value of $19.77M.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+9.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Herve Hoppenot holds in companies
Most Profitable Insider Trade
The most profitable trade made by Herve Hoppenot
Herve Hoppenot's Trading History
Incyte
Nov 12, 2025
Director
Informative Sell
19.77M
$35.69M
Bicycle Therapeutics
Sep 10, 2025
Director
Uninformative Buy
―
$82.00K
Maze Therapeutics, Inc.
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Herve Hoppenot's performance on stock
You May Also Like
Herve Hoppenot insider profile FAQ
What is the percentage of profitable transactions made by Herve Hoppenot?
The percentage of profitable transactions made by Herve Hoppenot is 50%.
What is the average return per transaction made by Herve Hoppenot?
The average return per transaction made by Herve Hoppenot is 9.60%.
What stocks does Herve Hoppenot hold?
Herve Hoppenot holds: INCY, BCYC, MAZE stocks.
What was Herve Hoppenot’s latest transaction?
Herve Hoppenot latest transaction was an Informative Sell of $19.77M.
What was Herve Hoppenot's most profitable transaction?
Herve Hoppenot’s most profitable transaction was an Informative Buy of INCY stock on May 3, 2018. The return on the trade was 33.10%.
What is Herve Hoppenot's role in Incyte?
Herve Hoppenot's role in Incyte is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.